Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR4 | Q5NUL3 | 13/20 | 0.52 |
| ▸ | FFAR1 | O14842 | 5/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | PKM | P14618 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | NTRK1 | P04629 | 2/20 | 0.35 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.33 |
| ▸ | IDO1 | P14902 | 2/20 | 0.32 |
| ▸ | HCAR1 | Q9BXC0 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL515495 | 0.77 | L3MBTL1 (0.47) | ALDH1A1HPGDHTTL3MBTL1SLC6A2 | |
| SCHEMBL15739404 | 0.77 | SRC (0.33) | FFAR4ALDH1A1L3MBTL1 | |
| SCHEMBL1715944 | 0.77 | IDO1 (0.55) | FFAR4FFAR1IDO1 | |
| SCHEMBL5542283 | 0.77 | FFAR4 (0.52) | FFAR4FFAR1ALDH1A1PKMHPGD | |
| Hydrochloric Acid SCHEMBL1715862 | 0.76 | IDO1 (0.56) | FFAR4FFAR1IDO1 | |
| SCHEMBL11406620 | 0.75 | SRC (0.40) | ALDH1A1HPGDHTTIDO1 | |
| SCHEMBL12361207 | 0.74 | FFAR4 (0.49) | FFAR4FFAR1ALDH1A1PKMHPGD | |
| SCHEMBL6762797 | 0.74 | FFAR4 (0.49) | FFAR4FFAR1ALDH1A1PKMHPGD | |
| SCHEMBL2091829 | 0.74 | IDO1 (0.59) | FFAR4FFAR1ALDH1A1HTTIDO1 | |
| SCHEMBL10563241 | 0.73 | ADH1B (0.43) | FFAR4FFAR1ALDH1A1PKMHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2570418-A2 | 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles compound | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2013-03-20 | — | — | EP | disclosed |
| EP-1555267-B1 | 2,3-DIHYDRO-6-NITROIMIDAZO[2,1-b]OXAZOLES | OTSUKA PHARMA CO LTD (JP) | 2013-01-16 | — | — | EP | disclosed |
| US-7262212-B2 | 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2007-08-28 | — | — | US | disclosed |
| US-20060094767-A1 | 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2006-05-04 | — | — | US | disclosed |
| EP-1555267-A1 | 2,3-DIHYDRO-6-NITROIMIDAZO 2,1-b OXAZOLES | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2005-07-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060094767-A1 | 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles | NR2C2, NR4A3, NR4A2 | FFAR4 338/4885FFAR1 105/4885ALDH1A1 355/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.